Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rineterkib
LTT462 · 1 trial · 1 indication
Confirmed ORR using RECIST v1.1, per local assessment
| Arm | Type | Description |
|---|---|---|
| LXH254 + LTT462 | EXPERIMENTAL | - |
| LXH254 + trametinib | EXPERIMENTAL | - |
| LXH254 + ribociclib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LXH254 | DRUG | LXH254 will be supplied as tablet for oral use. |
| LTT462 | DRUG | LTT462 will be supplied as hard gelatin capsule for oral use. |
| Trametinib | DRUG | Trametinib will be supplied as film-coated tablet for oral use |
| Ribociclib | DRUG | Ribociclib will be supplied in tablets and hard gelatin capsules. |
Inclusion Criteria: Male or female must be ≥ 12 years For adolescents only (12-17 years): body weight \> 40kg Histologically confirmed unresectable or metastatic cutaneous melanoma Previously treated for unresectable or metastatic melanoma: * Participants with NRAS mutation: * Participants must h...
Top 20 of 52 competitors
LTT462 is an investigational small molecule developed by Novartis AG for the treatment of melanoma. It is being studied in patients with previously treated unresectable or metastatic melanoma. LTT462 is a biomarker-selected therapy, meaning trial enrollment is guided by specific molecular characteristics of a patient's tumor.
LTT462 is being evaluated for the treatment of previously treated unresectable or metastatic melanoma. It is studied as part of a combination regimen in a Phase 2 trial. The trial enrolls patients whose tumors meet biomarker selection criteria, and it is currently active but no longer recruiting participants.
LTT462 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis is the sponsor of the clinical program evaluating LTT462 in melanoma.
LTT462 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 2 study is active but not recruiting, and no trials of LTT462 have been completed to date.
LTT462 is being studied in the Phase 2 trial NCT04417621, titled Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma. The trial has enrolled 134 patients across the United States, Argentina, Australia, Belgium, France, Germany, Israel, Italy, the Netherlands, Norway, Switzerland, and the United Kingdom.
Yes. The Phase 2 trial of LTT462, NCT04417621, is a randomized, controlled study. It is not double blinded. The trial enrolled 134 patients with previously treated unresectable or metastatic melanoma and is currently active but not recruiting new participants.